Resumen
Multiple myeloma is a cancer of the bone marrow which accounts for approximately 1.8% of all cancer diagnoses worldwide. The clinical outcomes for patients with multiple myeloma have significantly improved in the most recent decade, resulting in better quality of life and prolonged survival. However, this remains a largely incurable disease with inevitable relapse and resistance to medical treatment. Furthermore, there is a cohort of high-risk myeloma patients who possess disease characteristics which predispose them to worse clinical outcomes and poor response to treatment. There is a pressing need to develop new treatment strategies for myeloma, particularly therapeutic approaches which would be successful in high-risk patients. Recently there has been promising advances in cell-based immunological therapies for myeloma; however, further studies are needed to fully establish their long-term efficacy and their role in the treatment of high-risk patients.